CClinicalTrials.gg
RecruitingNCT06345326GON-B/PRFUpdated Apr 3, 2024

Greater Occipital Nerve Block Versus Pulse Radiofrequency in Migraine

An interventional study of Greater occipital nerve block in Migraine, sponsored by Adiyaman University Research Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Adiyaman University Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2023, registered Mar 2024).
  • Started Jan 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the study is to evaluate the clinical efficacy of the repeated greater occipital nerve(GON) blokcs with GON pulse radiofreaquency (PRF)

Read the detailed description

The nerve blocks will be performed at the Cervical-2 (C2) level with ultrasound guidance.Also , the PRF will be done as above proximally.

02

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • greater occipital nerve block
  • pulse radiofrequency
03

In context

Migraine Disorders

1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.

This study's planned enrollment of 68 is below the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Adiyaman University Research Hospital is the lead sponsor of 48 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ICHD- migraine with minimum 4 attacks
  • no benefit with proflactic therapies

Exclusion criteria

Exclusion Criteria:

  • primary headhache other than migraine according to ICHD
  • the change of medical teatment of migrane in last 1 month.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Repeated greater occipital nerve block

    In this arm, all the participiants will receive ultrasound guided greater occipital nerve block for a week, for 4 weeks with ultrasound guidiance at the level C2

    Other: Greater occipital nerve block

  • Experimental
    Greater occipital nerve pulse radiofrequency

    In this arm, all the participiants will receive ultrasound guided greater occipital nerve pulse radiofrequency with ultrasound guidiance at the level C2

    Other: Greater occipital nerve block

Interventions

  • OtherGreater occipital nerve block

    The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.

    Also known as: Pulse radiofrequency

06

What researchers measure

Primary outcomes

  1. NRS

    Numeric rating scala

    Time frame: Before the application then every month following the intervention for 3 months

Secondary outcomes

  1. Complications

    vertigo, dizzines, hypotension , bleeding, local pain ect.

    Time frame: Before the application then every month following the intervention for 3 months

  2. the frequency of headhache

    how many times the headhache occured

    Time frame: Before the application then every month following the intervention for 3 months

07

Study locations

1 of 1 sites recruiting
  • Ankara City Hospital Bilkent
    Ankara, 06680, Turkey
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345326
Lead sponsor
Adiyaman University Research Hospital
Collaborators
Ankara City Hospital Bilkent
Responsible party
Dr. Ülkü Sabuncu (M.D., Ankara City Hospital Bilkent) — Principal investigator
First posted
Apr 3, 2024
Start date
Jan 15, 2023
Primary completion
Mar 30, 2024 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Apr 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion